BRIEF published on 12/09/2025 at 14:55, 1 month 2 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 1 month 2 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 1 month 2 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 2 months ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 2 months ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 2 months 6 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 2 months 6 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 3 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 3 months 1 day ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 3 months 24 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 01/10/2026 at 05:10, 1 day 18 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 22 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 2 days ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 2 days ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/11/2026 at 22:20, 1 hour 13 minutes ago Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Published on 01/10/2026 at 21:25, 1 day 2 hours ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 10 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 2 days 1 hour ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:30, 2 days 5 hours ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 5 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 5 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 3 days 2 hours ago Biannual report on SEB S.A.’S liquidity agreement
